ArrowMark Colorado Holdings LLC Reduces Stock Holdings in Sotera Health (NASDAQ:SHC)

ArrowMark Colorado Holdings LLC reduced its stake in Sotera Health (NASDAQ:SHC - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,351,552 shares of the company's stock after selling 22,215 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 1.18% of Sotera Health worth $45,849,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SHC. Two Seas Capital LP boosted its holdings in Sotera Health by 624.0% in the fourth quarter. Two Seas Capital LP now owns 2,896,136 shares of the company's stock worth $39,619,000 after acquiring an additional 2,496,136 shares in the last quarter. Norges Bank bought a new position in shares of Sotera Health in the fourth quarter valued at approximately $12,764,000. Walleye Capital LLC raised its position in Sotera Health by 818.2% in the 4th quarter. Walleye Capital LLC now owns 775,000 shares of the company's stock valued at $10,602,000 after buying an additional 690,597 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Sotera Health by 27.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,143,955 shares of the company's stock worth $43,004,000 after acquiring an additional 673,979 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Sotera Health by 45.1% in the fourth quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company's stock valued at $22,308,000 after purchasing an additional 507,147 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company's stock.

Wall Street Analysts Forecast Growth

SHC has been the topic of several recent analyst reports. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $14.00 to $17.00 in a research report on Monday. Piper Sandler dropped their target price on Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, Barclays decreased their target price on Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.80.

Sotera Health Stock Up 1.1 %

Shares of SHC traded up $0.15 during trading hours on Thursday, hitting $13.30. The company had a trading volume of 427,934 shares, compared to its average volume of 1,184,788. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 53.20 and a beta of 1.88. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08. The firm has a fifty day moving average price of $11.39 and a 200-day moving average price of $12.98.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The business had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company's revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business posted $0.13 EPS. On average, equities research analysts forecast that Sotera Health will post 0.61 EPS for the current fiscal year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.